Background {#Sec1}
==========

Among cancers, prostate cancer ranks second globally in morbidity and fifth in mortality \[[@CR1]\]. Radiotherapy (RT) and surgery have played leading roles in the radical treatment of localized prostate cancer \[[@CR2]\]. Technological improvements in RT, such as intensity-modulated RT (IMRT) and particle therapy, can provide dose escalation without increasing toxicity in the surrounding normal tissues \[[@CR3]\]. Several studies demonstrated that biochemical failure rates were reduced by escalating the radiation dose \[[@CR4]--[@CR7]\].

Carbon-ion RT (CIRT) for cancer treatment in humans was started in 1994 at the National Institute of Radiological Sciences (Chiba, Japan), and the first CIRT clinical trial for prostate cancer was started in 1995 \[[@CR8]\]. CIRT offers biological and physical advantages over conventional RT with X-rays. Carbon-ion beams have an estimated threefold higher relative biological effectiveness (RBE) than X-rays \[[@CR9], [@CR10]\]. Regarding the physical aspect, the carbon-ion beam can create a better dose distribution based on the ability of accelerated carbon ions to release a maximum amount of energy at the end of their track, resulting in a Bragg peak \[[@CR11]\]. These features can permit dose escalation for tumors with less toxicity in normal tissues. In fact, favorable clinical outcomes of CIRT for prostate cancer have been reported \[[@CR12], [@CR13]\].

The first clinical operation at the ion beam Radiation Oncology Center in Kanagawa (i-ROCK) at Kanagawa Cancer Center (KCC) was started in 2015 \[[@CR14]\]. The i-ROCK is a compact carbon-ion facility designed by the Japanese National Institute of Radiological Sciences for widespread use and is based on a synchrotron accelerator that feeds four treatment rooms. All patients have been treated with CIRT using the spot scanning method since the opening of i-ROCK. The spot scanning method is a 3D scanning beam delivery method that uses narrow pencil beams of carbon ions to cover the entire target volume \[[@CR15]\]. The target volume is decomposed into thin longitudinal layers that are irradiated layer by layer with the pencil beam \[[@CR16]\]. A pencil beam can be deflected magnetically in horizontal and vertical directions to irradiate a tumor slice \[[@CR17]\]. By reducing the energy stepwise and repeating the irradiation for each slice, a tumor can be irradiated according to its shape from the most distal end of the target to the proximal end \[[@CR18]--[@CR20]\]. This unique irradiation technique offers a more conformal dose distribution to the shape of the tumor.

In i-ROCK, the use of CIRT using the spot scanning method for prostate cancer was started in December 2015. The clinical outcomes of prostate cancer patients treated with CIRT using only the spot scanning method have not been investigated before. The present study thus aimed to analyze the efficacy and toxicities of CIRT using the spot scanning method for patients with prostate cancer.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

In total, 253 consecutive patients with prostate cancer treated with CIRT at KCC between December 2015 and December 2017 were analyzed in the present study. Clinical records were collected in April 2020. The eligibility criteria for this study were as follows: (i) histological diagnosis of prostate adenocarcinoma, (ii) cT1bN0M0 to T3bN0M0 according to the 7th UICC classification, (iii) performance status of 0--2, (iv) age of 20 years or older, and (v) no previous treatment for prostate cancer excluding androgen deprivation therapy (ADT). The patients were classified using the D'Amico risk group classification \[[@CR21]\]. The study was approved by the institutional review board of KCC (approval number: 2019--145). Written informed consent was obtained from all patients.

CIRT {#Sec4}
----

Patients were placed in the supine position. The patients were positioned on a vacuum mattress (BlueBAG: Elekta AB, Stockholm, Sweden) and immobilized using thermoplastic shells (Shellfitter: Kuraray, Tokyo, Japan). Enema was used before computed tomography (CT) for CIRT planning. The rectum was emptied as much as possible using a laxative and antiflatulent before each session, and enema was performed if the patient did not defecate within 24 h of treatment. The patients urinated and watered 60 min before CT. A set of CT images with 2 mm-thick slices was taken for treatment planning.

Contouring of target volumes and normal tissues was performed using MIM maestro software version 5.6. (MIM Software Inc., Cleveland, OH, USA). Dose calculation and optimization were performed using the Monaco version 5.20 system (Elekta AB).

The gross tumor volume was not defined. The clinical target volume (CTV) included the entire prostate and proximal seminal vesicles. In the case of T3b prostate cancer, the ipsilateral seminal vesicles were included in the CTV \[[@CR22]\]. Prophylactic pelvic lymph node area was not included in the CTV \[[@CR23]\]. Planning target volume (PTV) 1 was created by adding anterior and lateral margins of 10 mm and a posterior margin of 5 mm to the CTV. Boost therapy was performed using PTV2, in which the posterior edge was set in front of the anterior wall of the rectum to reduce the rectal dose in the ninth course of the treatment \[[@CR24], [@CR25]\]. The rectum was delineated as the organ at risk from 10 mm above the upper margin of the PTV to 10 mm below the lower margin of the PTV.

The total dose was set at 51.6 Gy (RBE). After the first eight fractions were delivered using PTV1, boost therapy was performed using PTV2. The PTV was covered by ≥95% of the prescribed dose, and the PTV max dose was limited to \< 105% of the prescribed dose. The dose constraint for rectum was aimed at V80% \< 10 ml.

CIRT was administered once daily for 4 days a week over 3 weeks. All patients were treated using the spot scanning method. CIRT was performed from both the right and left sides of the patient. One port was used for each treatment session. In each treatment session, a computer-aided online 2-D positioning system was employed to verify the positioning accuracy to less than 1 mm. In-room CT was conducted at the end of the first treatment session to confirm position accuracy. If position accuracy was confirmed, in-room CT was conducted at the fifth and ninth treatment sessions to reconfirm the patient's position. If position accuracy was not sufficient, additional in-room CT was considered as necessary.

Follow-up {#Sec5}
---------

A urologist and a radiation oncologist conducted patient follow-up at 3 month intervals for the first 3 years after CIRT and at intervals of 6 months thereafter. Prostate specific antigen (PSA) was measured at each follow-up visit. Biochemical relapse was defined using the Phoenix definition, that is, the nadir PSA level plus 2 ng/ml \[[@CR26]\]. The duration of biochemical relapse-free survival (BFS) was calculated from the start of CIRT to the date of the event.

Toxicities were assessed according to the Common Terminology Criteria for Adverse Events version 4.0. Acute toxicity was defined as events occurring up to 3 months after the initiation of CIRT, and late toxicity was defined as events occurring after 3 months. The worst toxicity grade was considered the final grade of toxicity.

ADT {#Sec6}
---

Urologists administered ADT. ADT was not administered to low-risk patients. Neoadjuvant ADT was administered for 4--8 months to intermediate-risk patients, whereas high-risk patients received a total of 24 months of neoadjuvant plus adjuvant ADT.

Statistical analysis {#Sec7}
--------------------

Statistical analysis was performed using STATA software (version 13.1, Texas, USA). A *p* value of \< 0.05 was considered significant. BFS, and the cumulative rates of late toxicity were estimated using the Kaplan--Meier method. BFS rates in each risk group were compared via log-rank analysis. Patient characteristics were compared using Fisher's exact test. The correlation of clinical variables with toxicities was assessed via logistic regression analysis.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

Patient characteristics are summarized in Table [1](#Tab1){ref-type="table"}. The median age was 70 (range, 47--86) years. The median follow-up duration was 35.3 (range, 4.1--52.9) months. Among 253 patients, 8, 88, and 157 patients were classified as having low, intermediate, and high risks, respectively. The median ages in the low-, intermediate-, and high-risk group were 68 (range, 59--75), 68 (range, 48--81), and 70 (range, 47--86) years, respectively. Significant difference was observed between the intermediate- and high-risk groups (*p* = 0.034). All patients completed CIRT on schedule. ADT was administered to 244 patients, and the median duration of ADT was 22.8 (range, 2.3--116.9) months. A total of 4 patients underwent transurethral resection of the prostate (TURP) in a median of 14 (range, 9--15) years before CIRT. Of these 4 patients, 2 were classified as intermediate-risk group and 2 as high-risk group. Table 1Patient characteristics (*n* = 253)Characteristicsn (%)Follow-up duration, months, median (range)24.3 (4.1--39.5)Age, years, median (range)70 (47--86)T stage 1c49 (19.4%) 2a79 (31.2%) 2b35 (13.8%) 2c53 (20.9%) 3a27 (10.7%) 3b10 (4.0%)Pretreatment PSA, ng/ml, median (range)8.6 (3.33--187)  \< 10147 (58.1%) 10 ≤ 2073 (28.9%) 20 ≤33 (13.0%)Gleason score 614 (5.5%) 7117 (46.2%) 879 (31.2%) 943 (17.0%) 100 (0.0%)D'Amico classification low8 (3.2%) intermediate88 (34.8%) high157 (62.1%)ADT none9 (3.6%) neoadjuvant87 (34.4%) neoadjuvant and adjuvant157 (62.1%)Complications, histories Diabetes mellitus25 (9.9%) Internal use of anticoagulants41 (16.2%) Benign prostate hyperplasia18 (7.1%) TURP4 (1.6%)*PSA* prostate specific antigen, *ADT* androgen deprivation therapy, *TURP* transurethral resection of the prostate

BFS rates {#Sec10}
---------

Four patients died during the observation period. All patients died of other diseases, such as gastric cancer, lung cancer, hepatocellular cancer and pancreatic cancer. Prostate cancer was diagnosed as the primary type of cancer in these four patients.

The BFS rate is presented in Fig. [1](#Fig1){ref-type="fig"}**.** The BFS rates in the low-, intermediate-, and high-risk groups at 3 years were 87.5, 88.0, and 97.5%, respectively (*p* = 0.036). Biochemical relapse was observed in 14 patients. Biochemical relapse was observed at a median of 25.7 (range, 0.8--42.2) months after CIRT. Significant difference was observed between age and biochemical relapse. The median ages with and without biochemical relapse were 64 (range, 50--86) and 70 (range, 47--85) years, respectively (*p* = 0.007). Significant differences were not observed in other patient characteristics. In eleven of fourteen patients, the PSA level was decreased without any treatment such as ADT. Two patients received ADT immediately after the diagnosis of PSA failure without radiological confirmation of clinical recurrence. Clinical recurrence was observed in one patient. A patient who was classified as high-risk group experienced pelvic node and lung metastases at 36.6 months after CIRT. Fig. 1Biochemical relapse-free rate. The biochemical relapse-free rate in the low-, intermediate-, and high-risk groups at 3 years was 87.5, 88.0, and 97.5%, respectively (P = 0. 036)

Toxicities {#Sec11}
----------

Table [2](#Tab2){ref-type="table"} shows the maximal acute and late toxicities in the present study. The acute genitourinary (GU) toxicity grades were one in 52 patients (20.6%) and two in 12 patients (4.7%). Grade 3 or greater acute GU toxicity was not observed. Among acute GU toxicities, urinary frequency was the major symptom observed. Grades 1 and 2 urinary frequency were observed in 36 (14.8%) and 12 (4.7%) patients, respectively. The second highest observed symptom was urinary stricture, with grades 1 and 2 urinary stricture in 12 (4.7%) and 3 (1.2%) patients, respectively. The acute gastrointestinal (GI) toxicity grade was one in two patients (0.8%). Both of these two patients experienced diarrhea. Grade 2 or greater acute GI toxicity was not observed. Table 2ToxicitiesToxicities*n* = 253Acute toxicitiesGrade 0Grade 1Grade 2Grade 3 or moreGU total189 (74.7%)52 (20.6%)12 (4.7%)0 urinary frequency210 (83.0%)34 (13.4%)9 (3.6%)0 urinary stricture238 (94.1%)12 (4.7%)3 (1.2%)0 urinary tract pain249 (98.4%)4 (1.6%)00 urinary urgency251 (99.2%)2 (0.8%)00GI total251 (99.2%)2 (0.8%)00 diarrhea251 (99.2%)2 (0.8%)00Late toxicitiesGrade 0Grade 1Grade 2Grade 3 or moreGU total185 (73.1%)52 (20.6%)16 (6.3%)0 urinary frequency214 (84.6%)26 (10.3%)11 (4.3%)0 hematuria238 (94.1%)14 (5.5%)1 (0.4%)0 urinary stricture245 (96.8%)5 (2.0%)3 (1.2%)0 urinary incontinence246 (97.2%)6 (2.4%)1 (0.4%)0 urinary urgency251 (99.2%)2 (0.8%)00GI total238 (94.1%)12 (4.7%)3 (1.2%)0 rectal hemorrhage238 (94.1%)12 (4.7%)3 (1.2%)0*GU* genitourinary, *GI* gastrointestinal

The late GU toxicity grades were one in 52 patients (20.6%) and two in 17 patients (6.7%). Grade 3 or greater late GU toxicity was not observed. Among the late GU toxicities, grades 1 and 2 hematuria were observed in 14 (5.5%) and one patient (0.4%), respectively. Grades 1 and 2 urinary frequency were observed in 28 (11.1%) and 11 (4.3%) patients, respectively, and grades 1 and 2 urinary stricture were observed in 5 (2.0%) and 3 (1.2%) patients, respectively.

The late GI toxicity grades were one in 12 patients (4.7%) and two in three patients (1.2%). Grade 3 or greater late GI toxicity was not observed. All late GI toxicities were rectal hemorrhage. Grades 1 and 2 GI toxicities were observed in median durations of 14.4 (range, 10.0--23.6) and 9.1 (range, 4.8--13.4) months after CIRT, respectively (*p* = 0.167). The cumulative incidence rate of any-grade late rectal toxicity is shown in Fig. [2](#Fig2){ref-type="fig"}. The 3-year cumulative incidence rate of any-grade late rectal toxicity was 6.1%. Fig. 2Cumulative incidence rate of late rectal toxicities. The 3-year cumulative incidence rate of any-grade late rectal toxicity was 6.1%

The predictive significance of clinical variables for the occurrence of late grade 2 toxicities was assessed via logistic regression analysis (Table [3](#Tab3){ref-type="table"}). A history of TURP was significantly associated with the occurrence of grade 2 late GU toxicity in univariate analysis (*p* = 0.008). The number of patients who developed grade 2 GU toxicity with and without a history of TURP was 2 (50.0%) and 2 (6.0%) patients, respectively. Although diabetes mellitus (DM) was tended to be associated with the occurrence of grade 2 late GU toxicity, significant relation was not observed in univariate analysis (*p* = 0.052). The number of patients who developed grade 2 late GU toxicity with and without DM was 4 (16.7%) and 13 (5.7%) patients, respectively. In multivariate analysis, significant predictor for grade 2 late GU toxicity was not detected. No significant predictor for GI toxicity was detected. Table 3Predictive significance of clinical factors for late grade 2 toxicitiesUnivariateMultivariateOR(95% CI)*p*-valueOR(95% CI)p-valueLate grade 2 GU toxicity (*n* = 17) Age1.00(0.93--1.07)0.9861.01(0.93--1.09)0.863 Risk group0.68(0.30--1.56)0.3631.31(0.27--6.45)0.741 ADT duration0.98(0.93--1.02)0.3370.96(0.88--1.05)0.407 DM3.32(0.99--11.15)0.0522.94(0.80--10.82)0.105 Anticoagulants0.31(0.04--2.38)0.2580.26(0.03--2.28)0.227 BPH1.72(0.36--8.14)0.496NA---- TURP15.60(2.05--118.58)**0.008**NA----Late grade 2 GI toxicity (*n* = 3) Age1.07(0.90--1.29)0.4381.09(0.0.88--1.35)0.422 Risk groupNA----NA---- ADT duration1.02(0.97--1.08)0.4030.98(0.82--1.18)0.850 DM4.93(0.43--56.53)0.1996.27(0.42--94.06)0.184 Anticoagulants2.63(0.23--29.64)0.4351.15(0.08--16.27)0.920 BPHNA----NA---- TURPNA----NA----*OR* Odds ratios, *CI* Confidence interval, *NA* not available, *GU* genitourinary, *GU* gastrointesitinal, *ADT* androgen deprivation therapy, *DM* diabetes mellitus, *BPH* benign prostate hyperplasia, *TURP* transurethral resection of the prostate

Discussion {#Sec12}
==========

We investigated the preliminary results of CIRT using the spot scanning method for prostate cancer in the present study. To the best of our knowledge, this is the first report about the clinical outcomes of prostate cancer patients after undergoing CIRT with the spot scanning method.

Late GI toxicity is often a problem with RT for prostate cancer. Technological improvements in RT, such as IMRT and particle therapy, can provide a better dose distribution to the target and spare the normal surrounding tissues. In patients with prostate cancer treated with high-dose 3DCRT, grade 2 or greater late GI toxicity was observed 14--24% of patients in a prior study \[[@CR27]--[@CR30]\]. Meanwhile, the rate of grade 2 or greater late GI toxicity was reduced to 5--15% using IMRT to spare the rectal dose \[[@CR31]--[@CR33]\].

Moreover, particle therapy can more strongly reduce the rectal dose than IMRT based on its sharp dose distribution to the target. According to results of a phase II clinical trial analyzing 84 patients treated with proton beam RT, the incidence of grade 2 late GI toxicity was 13% \[[@CR34]\]. Iwata et al. reported the results of a multi-institutional retrospective survey of proton therapy for prostate cancer in Japan, and the incidence rate of grade 2 or greater severe late GI toxicity was 4.6% \[[@CR35]\].

Late GI toxicity is also known as a dose-limiting factor in CIRT for prostate cancer. In a dose escalation study of CIRT for prostate cancer, grade 3 late GI toxicity developed in 36% of patients who received a dose of 72 Gy \[[@CR8]\]. However, according to a phase II clinical study of CIRT for prostate cancer using a total dose of 66 Gy delivered in 20 fractions, grade 2 GI toxicity was observed in 2% of the patients \[[@CR25]\]. Additionally, in a multi-institutional study of CIRT for prostate cancer, the incidence of grade 2 rectal toxicity was only 0.8% \[[@CR13]\]. Similar results were obtained in the present study. In the study of the correlation between late GI toxicity and CIRT, anticoagulation therapy was associated with a 2.7-fold risk of late GI toxicity \[[@CR36]\]. In the present study, significant correlation was not observed between anticoagulation therapy and late GI toxicity.

In this study, previous TURP was significantly associated with grade 2 late GU toxicity. A study of IMRT demonstrated that previous TURP was associated with late GU toxicity \[[@CR37]\]. Another study of IMRT, DM was reported as a predictive factor for late grade 2 or greater GU toxicities \[[@CR38]\]. In the present study, DM was tended to correlate with grade 2 late GU toxicity. In terms of late GU toxicity after CIRT, it was reported that longer ADT duration was a predictor of late GU toxicity \[[@CR39]\]. However, in the present study, a significant correlation between ADT duration and late GU toxicity was not observed. Few studies have assessed the correlation between ADT duration and late GU toxicity, therefore, further studies are required to assess the relationship between CIRT and GU toxicity.

Several studies have demonstrated dose response in prostate cancer \[[@CR4]--[@CR7]\]. Only ADT is not sufficient for the definitive treatment for prostate cancer; high-dose radiation therapy is required \[[@CR40]\]. On the basis of the very low α/β ratio for prostate cancer, hypofractionated radiotherapy would offer increased therapeutic benefit without increasing toxicity \[[@CR41]\]. In fact, several studies have reported the efficacy of moderate hypofractionated RT for patients with prostate cancer \[[@CR42]--[@CR45]\]. Moreover, the clinical outcomes of extreme hypofractionated RT for those with prostate cancer have been recently reported \[[@CR46]--[@CR48]\]. According to these features of prostate cancer and because of the biological and physical advantages in CIRT, it is considered that CIRT is appropriate for the management of prostate cancer. In fact, favorable BFS rates have been reported in patients treated with CIRT. Ishikawa et al. reported a 5 year BFS rate of 90.6% for patients with prostate cancer treated with CIRT at a total dose of 66 Gy (RBE) delivered in 20 fractions \[[@CR12]\]. In a multi-institutional analysis of CIRT, the 5 year BFS rates in the low-, intermediate-, and high-risk groups were 92, 89, and 92%, respectively \[[@CR13]\]. In the present study, the BFS rate was worst in the low-risk group and best in the high-risk group. The two major reasons to explain these results are as follows. First, the number of the low-risk patients was small, i.e., only eight patients. Therefore, the BFS rate in the low-risk group seemed to be relatively higher than that in the other group; furthermore, there was only one case of biochemical relapse. One of these eight low-risk patients experienced PSA elevation immediately after CIRT, which may have been a benign temporary PSA elevation called PSA bounce; however, its significance was unclear owing to immediate ADT after PSA elevation without any radiological confirmation of clinical recurrence. Second, high-risk patients received ADT for a longer duration. In the present study, the high-risk group underwent ADT for a total of 2 years; thus, high-risk patients received ADT at least 1 year after the completion of CIRT. Therefore, the observation period was not sufficient to estimate the BFS rate in our study, and further observation will be necessary to confirm our treatment outcome.

In the present study, biochemical failure was observed in 14 patients, with PSA levels decreasing without treatment in 11 patients. PSA fluctuations without any clinical signs of cancer recurrence after RT follow-up are known as PSA bounces, and they are often observed after brachytherapy and/or external beam RT \[[@CR49]\]. PSA bounces after low-dose brachytherapy occurs in 28--49% of patients using a 0.2 ng/ml definition \[[@CR49]--[@CR51]\]. In approximately 10% of patients, the PSA bounce exceeds the 2 ng/ml limit \[[@CR51]\]. Age was one of the first and most frequently described predictive factors of the PSA bounce \[[@CR49], [@CR50]\]. A similar tendency was observed in the present study. There has been no study of PSA fluctuations after CIRT. The clinical significance of PSA fluctuations is unclear, and further study is required.

The present study had several limitations such as its single-institutional nature and short observation period. More than 80% of late toxicities occurred within 2 years after CIRT \[[@CR37]\]; therefore, toxicities were evaluated for a sufficient period in the present study. Further observation with a large patient cohort will be necessary to confirm our clinical outcome.

Conclusions {#Sec13}
===========

The present study demonstrated that CIRT using the spot scanning method for patients with prostate cancer has a favorable outcome. Further observation with a large patient cohort will be necessary to confirm our clinical outcome.
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